Northland Securities reissued their hold rating on shares of DexCom (NASDAQ:DXCM) in a research note issued to investors on Thursday, June 6th, Stock Target Advisor reports. Northland Securities currently has a $125.00 target price on the medical device company’s stock.
“We present here a comparative assessment of 2.0 data readouts. Our global view is….we love Dexcom, but believe the story is going to be pressured on all fronts….top-line growth, margins, and market share. If this data is representative of the FDA submission (or part thereof), there is no doubt that Libre 2.0 will get an i” designation.”,” the firm’s analyst wrote.
Several other equities analysts also recently commented on DXCM. Zacks Investment Research upgraded DexCom from a hold rating to a buy rating and set a $139.00 target price for the company in a research report on Tuesday, April 30th. Piper Jaffray Companies lifted their price objective on DexCom to $173.00 and gave the company an overweight rating in a research report on Wednesday, May 1st. BidaskClub downgraded DexCom from a buy rating to a hold rating in a research report on Tuesday, March 26th. TheStreet cut DexCom from a c rating to a d+ rating in a research note on Friday, April 5th. Finally, ValuEngine cut DexCom from a strong-buy rating to a buy rating in a research note on Monday, April 1st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. DexCom currently has a consensus rating of Buy and a consensus target price of $150.65.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.12. The company had revenue of $280.50 million for the quarter, compared to analyst estimates of $246.10 million. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. DexCom’s revenue for the quarter was up 52.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.30) EPS. As a group, sell-side analysts expect that DexCom will post 0.81 earnings per share for the current year.
In other DexCom news, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $115.05, for a total value of $46,020.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Steven Robert Pacelli sold 3,116 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $149.65, for a total value of $466,309.40. The disclosure for this sale can be found here. Insiders have sold 63,545 shares of company stock worth $7,938,976 in the last quarter. 0.88% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of DexCom in the fourth quarter valued at approximately $107,191,000. Vanguard Group Inc grew its position in shares of DexCom by 11.5% in the third quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after purchasing an additional 816,247 shares during the last quarter. Two Sigma Advisers LP grew its position in shares of DexCom by 1,493.1% in the fourth quarter. Two Sigma Advisers LP now owns 694,814 shares of the medical device company’s stock valued at $83,239,000 after purchasing an additional 651,200 shares during the last quarter. Two Sigma Investments LP grew its position in shares of DexCom by 596.5% in the fourth quarter. Two Sigma Investments LP now owns 731,059 shares of the medical device company’s stock valued at $87,581,000 after purchasing an additional 626,098 shares during the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd acquired a new position in shares of DexCom in the fourth quarter valued at approximately $65,247,000. Hedge funds and other institutional investors own 96.41% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.